<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606927</url>
  </required_header>
  <id_info>
    <org_study_id>2020000710</org_study_id>
    <nct_id>NCT04606927</nct_id>
  </id_info>
  <brief_title>Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure</brief_title>
  <acronym>PUSH-AHF</acronym>
  <official_title>Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of loop diuretics to achieve decongestion is the current cornerstone of&#xD;
      therapy for acute heart failure. Unfortunately, there is a lack of evidence of how to guide&#xD;
      diuretic treatment. Recently, urinary sodium, as a response measure of diuretic response, has&#xD;
      been proposed as a target for therapy. The hypothesis of this study is that natriuresis&#xD;
      guided therapy in patients with acute heart failure will improve diuretic response,&#xD;
      decongestion, and reduce length of hospital stay, as well as heart failure&#xD;
      rehospitalisations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the effect of natriuresis guided therapy in acute heart failure to&#xD;
      improve diuretic response, decongestion, and clinical outcomes&#xD;
&#xD;
      Study design: Randomised, controlled, open label study&#xD;
&#xD;
      Study population: 310 patients admitted with the primary diagnosis of acute heart failure&#xD;
      requiring intravenous loop diuretics.&#xD;
&#xD;
      Intervention: natriuresis guided treatment versus standard of care&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      Co-primary outcome: total natriuresis after 24 hours, and first occurrence of all-cause&#xD;
      mortality or heart failure rehospitalisation at 6 months Secondary outcomes: 48- and 72-hours&#xD;
      natriuresis, length of hospital stay, percentage change in NT-proBNP at 48 and 72 hours.&#xD;
&#xD;
      Safety endpoint: doubling of serum creatinine at 24 or 48 hours, worsening heart failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total natriuresis after 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The first component of the co-primary end-point is total natriuresis after 24 h (mmol). To assess this, urine is collected for 24 hours after the first administration of diuretics according to the study protocol and natriuresis is calculated as the total amount of diuresis (L) multiplied by the urinary sodium concentration (mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First occurrence of all-cause mortality or heart failure rehospitalization after 180 days</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>48-hours natriuresis</measure>
    <time_frame>48 hours</time_frame>
    <description>48-hour natriuresis will be assessed by collecting urine for a second period of 24 hours after the first 24-hour urine collection according to the study protocol and natriuresis is calculated as the total amount of diuresis (L) multiplied by the urinary sodium concentration (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>72-hours natriuresis</measure>
    <time_frame>72 hours</time_frame>
    <description>72-hour natriuresis will be assessed by collecting urine for a third period of 24 hours after the second 24-hour urine collection according to the study protocol and natriuresis is calculated as the total amount of diuresis (L) multiplied by the urinary sodium concentration (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Variable</time_frame>
    <description>Number of days of the index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in NT-proBNP at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Relative NT-proBNP change (%) after 48 hours compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in NT-proBNP at 72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>Relative NT-proBNP change (%) after 72 hours compared with baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoint: doubling of serum creatinine at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The first safety endpoint is defined as number of patients with a doubling of serum creatinine at 24 hours compared with baseline serum creatinine.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoint: doubling of serum creatinine at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>The second safety endpoint is defined as the number of patients with a doubling of serum creatinine at 48 hours compared with baseline serum creatinine.</description>
  </other_outcome>
  <other_outcome>
    <measure>Worsening heart failure</measure>
    <time_frame>During the index hospitalization (variable)</time_frame>
    <description>The third safety endpoint is defined as the number of patients with worsening heart failure during hospitalization.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Heart Failure Acute</condition>
  <arm_group>
    <arm_group_label>Natriuresis guided treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natriuresis</intervention_name>
    <description>Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.</description>
    <arm_group_label>Natriuresis guided treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female â‰¥ 18 years of age&#xD;
&#xD;
          2. Primary diagnosis of acute /decompensated heart failure as assessed by treating&#xD;
             physician&#xD;
&#xD;
             a. Acute Heart failure can be de novo or exacerbation of known heart failure and&#xD;
             diagnosis is based on criteria in the ESC HF guidelines&#xD;
&#xD;
          3. Requirement of intravenous diuretic use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dyspnoea primarily due to non-cardiac causes&#xD;
&#xD;
          2. Patients with severe renal impairment receiving dialysis or requiring ultrafiltration&#xD;
&#xD;
          3. Inability to follow instructions&#xD;
&#xD;
          4. Any other medical conditions that may put the patient at risk or influence study&#xD;
             results in the investigator's opinion, or that the investigator deems unsuitable for&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jozine M. ter Maaten, MD, PhD</last_name>
    <phone>+31 50 316 2355</phone>
    <email>j.m.ter.maaten@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Damman, MD, PhD</last_name>
    <phone>+31 50 316 2355</phone>
    <email>k.damman@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozine M. ter Maaten, MD, PhD</last_name>
      <phone>+31 50 361 2355</phone>
      <email>j.m.ter.maaten@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Kevin Damman, MD, PhD</last_name>
      <phone>+31 50 361 2355</phone>
      <email>k.damman@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jozine ter Maaten</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>loop diuretics</keyword>
  <keyword>natriuresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

